Cardiovascular Drugs Practice Questions

Q: Which of the following is a common side effect of angiotensin-converting enzyme (ACE) inhibitors?

Dry cough. ***Dry cough*** - This is a well-known side effect of ACE inhibitors, occurring in up to 20% of patients. It is thought to be caused by the accumulation of **bradykinin** and **substance P** in the respiratory tract, as ACE is responsible for their degradation. - The cough is typically non-productive, persistent, and resolves upon discontinuation of the medication. *Bradycardia* - **Bradycardia**, or a slow heart rate, is not a common side effect of ACE inhibitors. - ACE inhibitors primarily work by reducing systemic vascular resistance and blood pressure, with minimal direct effect on heart rate. *Hypoglycemia* - **Hypoglycemia**, or low blood sugar, is not typically associated with ACE inhibitor use. - While some medications can affect glucose metabolism, ACE inhibitors do not directly cause hypoglycemia. *Constipation* - **Constipation** is not a common side effect of ACE inhibitors. - Gastrointestinal side effects are generally mild and less frequent with ACE inhibitors compared to some other drug classes.

Q: Which adrenergic receptor subtype is targeted by beta-blockers like propranolol to lower blood pressure and manage angina?

Beta-1. ***Beta-1*** - **Beta-1 adrenergic receptors** are primarily located in the **heart**, and their blockade leads to decreased heart rate, contractility, and ultimately, lower blood pressure and reduced myocardial oxygen demand in angina [1], [2]. - While propranolol is a non-selective beta-blocker, its cardiovascular therapeutic effects are predominantly mediated through **beta-1 receptor blockade** in the heart [2]. *Alpha-1* - **Alpha-1 adrenergic receptors** are found in **vascular smooth muscle** and mediate **vasoconstriction** when activated. - Blocking these receptors, as with prazosin, would cause **vasodilation** and a drop in blood pressure, but this is not the primary mechanism of action for propranolol [2]. *Alpha-2* - **Alpha-2 adrenergic receptors** are typically located presynaptically, where they inhibit **norepinephrine release**, and centrally, where they can reduce sympathetic outflow. - Drugs like clonidine target these receptors to lower blood pressure, which is a mechanism distinct from beta-blockers. *Beta-2* - **Beta-2 adrenergic receptors** are predominantly found in **bronchial smooth muscle** and **vascular smooth muscle**, mediating bronchodilation and vasodilation, respectively. - Blocking these receptors, as a non-selective beta-blocker like propranolol does, can lead to adverse effects like **bronchoconstriction** in asthmatic patients, but it is not the primary target for lowering blood pressure or treating angina.

Q: What is the primary mechanism of action of digoxin in the treatment of heart failure?

Inhibition of Na+/K+ ATPase. ***Inhibition of Na+/K+ ATPase*** - Digoxin directly inhibits the **sodium-potassium ATPase pump** in cardiac muscle cells, leading to an increase in intracellular sodium. - This increase in intracellular sodium then reduces the activity of the **sodium-calcium exchanger**, resulting in higher intracellular calcium levels and increased myocardial contractility (positive inotropy). *Inhibition of angiotensin II receptor* - This is the mechanism of action for **angiotensin receptor blockers (ARBs)**, which are used in heart failure to reduce vasoconstriction and aldosterone release. - Digoxin does not directly interact with the **renin-angiotensin-aldosterone system** at the receptor level. *Inhibition of aldosterone secretion* - Aldosterone secretion is primarily inhibited by medications like **ACE inhibitors** and **ARBs**, or directly by aldosterone antagonists such as spironolactone. - Digoxin does not have a direct effect on the **adrenal gland's production** of aldosterone. *Inhibition of beta-adrenergic receptors* - This is the primary mechanism of action of **beta-blockers**, which are used in heart failure to reduce heart rate, myocardial oxygen demand, and remodeling. - Digoxin has a **positive inotropic effect** and does not block beta-adrenergic receptors; in fact, it can have some vagomimetic effects that slow heart rate.

Q: Which of the following enzymes is inhibited by statins to lower cholesterol levels?

HMG-CoA reductase. ***HMG-CoA reductase*** * Statins (HMG-CoA reductase inhibitors) competitively block this enzyme, which is the **rate-limiting step** in cholesterol biosynthesis in the liver. * By inhibiting HMG-CoA reductase, statins reduce the synthesis of **mevalonate** and subsequently cholesterol, leading to a decrease in circulating LDL-C. *Acetyl-CoA carboxylase* * This enzyme is involved in **fatty acid synthesis**, not cholesterol synthesis. * It catalyzes the carboxylation of **acetyl-CoA to malonyl-CoA**, a key step in fatty acid elongation. *Fatty acid synthase* * This is a multienzyme complex responsible for the **synthesis of long-chain fatty acids** from acetyl-CoA and malonyl-CoA. * It plays no direct role in the synthesis of cholesterol. *Citrate lyase* * This enzyme is involved in the **synthesis of acetyl-CoA** from citrate in the cytoplasm, which can then be used for fatty acid or cholesterol synthesis. * While it provides a precursor for cholesterol, it is **not the direct rate-limiting step** targeted by statins.

Q: Which antihypertensive drug is known for blocking the angiotensin II receptor (AT1) and reducing vasoconstriction?

Losartan. ***Losartan*** - Losartan is an **angiotensin receptor blocker (ARB)**, specifically blocking the **AT1 receptor** to prevent angiotensin II from binding. - This action leads to **vasodilation**, reduced aldosterone secretion, and decreased blood pressure, without the cough side effect associated with ACE inhibitors. *Amlodipine* - Amlodipine is a **calcium channel blocker** that primarily causes **vasodilation** by relaxing vascular smooth muscle. - Its mechanism involves inhibiting the influx of calcium ions into vascular smooth muscle cells, not blocking angiotensin II receptors. *Hydralazine* - Hydralazine is a **direct arterial vasodilator** that acts to relax smooth muscle in the arterioles. - Its mechanism of action is not related to the renin-angiotensin-aldosterone system (RAAS) but rather to directly reducing peripheral vascular resistance. *Propranolol* - Propranolol is a **non-selective beta-blocker** that reduces blood pressure by decreasing heart rate, myocardial contractility, and renin release. - It does not directly block angiotensin II receptors but can indirectly affect the RAAS by reducing renin secretion.

Q: What are the effects of niacin on HDL and triglycerides in the management of familial combined hyperlipidemia?

Increases HDL; lowers triglycerides. Correct: Increases HDL; lowers triglycerides - Niacin (nicotinic acid) is known for its efficacy in significantly **raising high-density lipoprotein (HDL)** levels, typically by 15-35% [1]. - It also has a potent effect on **reducing triglyceride** levels by 20-50%, making it beneficial in dyslipidemias where both are deranged [1]. - This dual action makes niacin particularly useful in familial combined hyperlipidemia [2]. Incorrect: Decreases HDL; raises triglycerides - This option describes effects that are the opposite of niacin's known pharmacological actions on lipid profiles. - Niacin is clinically used to improve, not worsen, these lipid parameters. Incorrect: No significant effect on HDL; minor effect on triglycerides - This statement underestimates niacin's impact, as its primary clinical utility is derived from its substantial effects on both HDL increase and triglyceride reduction [1]. - Although it has varied effects, its impact is far from minor or insignificant on these lipid components. Incorrect: Increases both HDL and triglycerides - While niacin raises HDL, it consistently **lowers triglycerides**, particularly in conditions like familial combined hyperlipidemia where triglyceride elevation is a key feature [2]. - Therefore, the claim that it increases both is incorrect due to its opposite effect on triglycerides.

Q: Which antihypertensive medication is contraindicated in pregnancy due to its potential to cause fetal renal damage?

ACE inhibitors. ***ACE inhibitors*** - ACE inhibitors are **contraindicated in pregnancy (FDA Category D)** and can cause severe fetal renal damage, including **oligohydramnios**, **renal dysplasia**, and **anuria**, particularly when used in the second and third trimesters. - They inhibit fetal angiotensin II production, which is crucial for normal renal development and function. - **ARBs (Angiotensin Receptor Blockers)** share the same contraindication and risks. *Labetalol* - **Labetalol** is a **beta-blocker** commonly used to manage hypertension in pregnancy and is generally considered safe. - It does not have known associations with fetal renal damage. *Nifedipine* - **Nifedipine**, a **calcium channel blocker**, is another preferred agent for treating hypertension in pregnant women. - It is not contraindicated and is not associated with teratogenic effects on the fetal kidneys. *Methyldopa* - **Methyldopa** is often considered the **first-line antihypertensive** for chronic hypertension in pregnancy due to its long-standing safety record. - It works as a centrally acting alpha-agonist and does not cause fetal renal damage.

Q: In a patient taking amiodarone, which factor most contributes to its potential to cause thyroid dysfunction?

High iodine content of amiodarone. ***High iodine content of amiodarone*** - Amiodarone contains approximately **37% iodine by weight**, leading to a significant daily iodine load that can disrupt normal thyroid function. - This excessive iodine can induce both **hypothyroidism (Wolff-Chaikoff effect)** and **hyperthyroidism (Jod-Basedow effect)** in susceptible individuals. *Direct thyroid toxicity* - While amiodarone can cause direct cytotoxic effects on thyroid cells, this is a **less prominent mechanism** compared to its iodine content in causing dysfunction. - **Amiodarone-induced destructive thyroiditis** (Type 2 AIT) involves direct thyroid damage and release of preformed hormones, but the initial trigger for widespread dysfunction is often the iodine. *Inhibition of TSH secretion* - Amiodarone does not primarily inhibit **TSH secretion**; in fact, TSH levels may be altered as a *result* of amiodarone's effects on thyroid hormone synthesis or release. - **Hypothyroidism** caused by amiodarone is typically characterized by **elevated TSH** due to reduced thyroid hormone production. *Inhibition of peripheral T4 to T3 conversion* - Amiodarone does inhibit the **peripheral conversion of T4 to T3** by blocking the 5'-deiodinase enzyme. - While this contributes to changes in thyroid hormone levels (e.g., elevated T4, reduced T3), it is **not the primary factor** responsible for the wide range of amiodarone-induced thyroid dysfunctions (hyper- and hypothyroidism), which are more directly linked to its high iodine load.

Q: Which of the following pharmacological agents can be used to induce stress during myocardial radionucleotide perfusion imaging?

All of the options. ***All of the options*** - **Dipyridamole**, **adenosine**, and **dobutamine** are all pharmacological agents commonly used to induce stress for myocardial perfusion imaging. - They produce coronary vasodilation (dipyridamole, adenosine) or increased myocardial oxygen demand (dobutamine) to unmask **ischemia**. *Dipyridamole* - **Dipyridamole** inhibits adenosine reuptake and phosphodiesterase, leading to increased extracellular adenosine, causing **coronary vasodilation**. - Its use can result in a steal phenomenon where blood is diverted from stenosed areas to healthy vessels. *Adenosine* - **Adenosine** is a direct vasodilator of coronary arteries, creating a disparity in blood flow between normal and stenotic vessels. - It has a very short half-life (~10 seconds), allowing for rapid onset and offset of its effects. *Dobutamine* - **Dobutamine** is a beta-1 adrenergic agonist that increases heart rate and myocardial contractility, thereby increasing myocardial oxygen demand. - It is often used as a stress agent when patients have contraindications to vasodilators.

Q: What is the mechanism of action of nicorandil?

K+ channel opener. ***K+ channel opener*** - **Nicorandil** acts as a **potassium channel opener**, specifically targeting ATP-sensitive potassium channels (K-ATP channels) in vascular smooth muscle - Opening these channels leads to **hyperpolarization** of the cell membrane, causing relaxation of smooth muscle and **vasodilation** - Nicorandil also has a **nitrate-like effect**, providing a dual mechanism for its antianginal action - This mechanism makes it effective in **stable angina** and **coronary vasospasm** *K+ channel blocker* - Potassium channel blockers (e.g., certain antiarrhythmics like amiodarone) inhibit potassium efflux, leading to **prolonged repolarization** and increased action potential duration - This mechanism is opposite to nicorandil's action and is used for **antiarrhythmic purposes**, not for vasodilation - Would cause vasoconstriction rather than the vasodilation seen with nicorandil *Na+ channel blocker* - Sodium channel blockers (e.g., local anesthetics, Class I antiarrhythmics) inhibit sodium influx, thereby **stabilizing cell membranes** and reducing excitability - This mechanism does not explain the **vasodilation** characteristic of nicorandil - Primarily used for arrhythmias, local anesthesia, or neurological conditions *Cl- channel blocker* - Chloride channel blockers are not a primary mechanism for drugs producing **vasodilation** like nicorandil - Their effects are typically related to **fluid secretion** or **cell volume regulation** (e.g., in cystic fibrosis or secretory diarrhea) - This mechanism is distinct from nicorandil's cardiovascular actions

Question 1

Which of the following is a common side effect of angiotensin-converting enzyme (ACE) inhibitors?

Accepted Answer

Dry cough

Answer

Bradycardia

Answer

Hypoglycemia

Answer

Constipation

Question 2

Which adrenergic receptor subtype is targeted by beta-blockers like propranolol to lower blood pressure and manage angina?

Accepted Answer

Beta-1

Answer

Alpha-1

Answer

Alpha-2

Answer

Beta-2

Question 3

What is the primary mechanism of action of digoxin in the treatment of heart failure?

Accepted Answer

Inhibition of Na+/K+ ATPase

Answer

Inhibition of angiotensin II receptor

Answer

Inhibition of aldosterone secretion

Answer

Inhibition of beta-adrenergic receptors

Question 4

Which of the following enzymes is inhibited by statins to lower cholesterol levels?

Accepted Answer

HMG-CoA reductase

Answer

Acetyl-CoA carboxylase

Answer

Fatty acid synthase

Answer

Citrate lyase

Question 5

Which antihypertensive drug is known for blocking the angiotensin II receptor (AT1) and reducing vasoconstriction?

Accepted Answer

Losartan

Answer

Amlodipine

Answer

Hydralazine

Answer

Propranolol

Question 6

What are the effects of niacin on HDL and triglycerides in the management of familial combined hyperlipidemia?

Accepted Answer

Increases HDL; lowers triglycerides

Answer

Decreases HDL; raises triglycerides

Answer

No significant effect on HDL; minor effect on triglycerides

Answer

Increases both HDL and triglycerides

Question 7

Which antihypertensive medication is contraindicated in pregnancy due to its potential to cause fetal renal damage?

Accepted Answer

ACE inhibitors

Answer

Labetalol

Answer

Nifedipine

Answer

Methyldopa

Question 8

In a patient taking amiodarone, which factor most contributes to its potential to cause thyroid dysfunction?

Accepted Answer

High iodine content of amiodarone

Answer

Direct thyroid toxicity

Answer

Inhibition of TSH secretion

Answer

Inhibition of peripheral T4 to T3 conversion

Question 9

Which of the following pharmacological agents can be used to induce stress during myocardial radionucleotide perfusion imaging?

Accepted Answer

All of the options

Answer

Adenosine

Answer

Dobutamine

Answer

Dipyridamole

Question 10

What is the mechanism of action of nicorandil?

Accepted Answer

K+ channel opener

Answer

Cl- channel blocker

Answer

K+ channel blocker

Answer

Na+ channel blocker

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?